- Home
- BVFL vs CRVS Comparison
BVFL vs CRVS Comparison
Compare BVFL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- CRVS
- Stock Information
- Founded
- BVFL 1873
- CRVS 2014
- Country
- BVFL United States
- CRVS United States
- Employees
- BVFL N/A
- CRVS N/A
- Industry
- BVFL Savings Institutions
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- BVFL Finance
- CRVS Health Care
- Exchange
- BVFL Nasdaq
- CRVS Nasdaq
- Market Cap
- BVFL 162.8M
- CRVS 161.4M
- IPO Year
- BVFL N/A
- CRVS 2016
- Fundamental
- Price
- BVFL $14.64
- CRVS $5.13
- Analyst Decision
- BVFL
- CRVS Buy
- Analyst Count
- BVFL 0
- CRVS 3
- Target Price
- BVFL N/A
- CRVS $5.75
- AVG Volume (30 Days)
- BVFL 14.7K
- CRVS 385.2K
- Earning Date
- BVFL 10-23-2024
- CRVS 11-05-2024
- Dividend Yield
- BVFL N/A
- CRVS N/A
- EPS Growth
- BVFL 44.67
- CRVS N/A
- EPS
- BVFL 1.41
- CRVS N/A
- Revenue
- BVFL $37,406,000.00
- CRVS N/A
- Revenue This Year
- BVFL N/A
- CRVS N/A
- Revenue Next Year
- BVFL N/A
- CRVS N/A
- P/E Ratio
- BVFL $10.16
- CRVS N/A
- Revenue Growth
- BVFL 3.92
- CRVS N/A
- 52 Week Low
- BVFL $9.86
- CRVS $1.05
- 52 Week High
- BVFL $15.00
- CRVS $5.19
- Technical
- Relative Strength Index (RSI)
- BVFL 74.57
- CRVS 73.92
- Support Level
- BVFL $14.11
- CRVS $3.90
- Resistance Level
- BVFL $14.50
- CRVS $4.75
- Average True Range (ATR)
- BVFL 0.23
- CRVS 0.37
- MACD
- BVFL -0.01
- CRVS 0.02
- Stochastic Oscillator
- BVFL 100.00
- CRVS 95.45
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. It offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, business checking as well as certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).